Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer Following First Line Platinum Based Chemotherapy.

NCT01844986 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01844986
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01844986 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer Following First Line Platinum Based Chemotherapy.
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Active, not recruiting
Start date
August 26, 2013
Completion date
August 29, 2028
Enrollment
450 (actual)
Sites
177

Conditions

As the registry lists them; a condition with its own page is linked.

advanced ovarian cancer, brca mutation, complete response, figo stage iii-iv, first line platinum chemotherapy, newly diagnosed, partial response